White Paper: A new way to study cytokine release syndrome

An in vivo CRS Evaluation Study in humanised mouse models can deliver fast, reproducible, and translatable data about drug safety in just two weeks. A humanised mouse platform offers the unique ability to preclinically analyse a fully systemic response that involves human immune cells and surrounding tissues. Furthermore, the platform also allows for efficacy testing and dose ranging.

By using mice humanised with cells from multiple donors, developers can generate a diverse data set that gives a more comprehensive and accurate prediction of what will happen in the clinic. Robust, diversified preclinical data not only protects future patients but also makes a therapeutic more attractive to investors.

Download the latest CRS White Paper, brought to you by The Jackson Laboratory, to learn more about:

  • Examining CRS responses in diverse patient populations
  • A cutting-edge PBMC humanised platform for more preclinically predictive data
  • The benefits of in vivo vs. in vitro studies
  • Performing dose-ranging studies to determine the ideal balance of safety and efficacy in novel therapeutics

Download the White Paper.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free